Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

PRMT6 promotes lung tumor progression via the alternate activation of tumor-associated macrophages.

Avasarala S, Wu PY, Khan SQ, Yanlin S, Van Scoyk M, Bao J, Di Lorenzo A, David O, Bedford MT, Gupta V, Winn RA, Bikkavilli RK.

Mol Cancer Res. 2019 Oct 16. pii: molcanres.0204.2019. doi: 10.1158/1541-7786.MCR-19-0204. [Epub ahead of print]

PMID:
31619507
2.

Engaging African American Men as Citizen Scientists to Validate a Prostate Cancer Biomarker: Work-in-Progress.

Watson KS, Henderson V, Murray M, Murphy AB, Levi JB, McDowell T, Holloway-Beth A, Gogana P, Dixon MA, Moore L, Hall I, Kimbrough A, Molina Y, Winn RA.

Prog Community Health Partnersh. 2019;13(5):103-112. doi: 10.1353/cpr.2019.0043.

3.

Building Cross-Institutional Collaborative Infrastructure and Processes: Early Lessons From the Chicago Cancer Health Equity Collaborative.

Simon MA, Fitzgibbon M, Ciecierski C, Cooper JM, Martinez E, Tom L, Kanoon J, Feinglass J, Warnecke R, Stuart M, Stern M, Filus L, Winn RA.

Prog Community Health Partnersh. 2019;13(5):5-13. doi: 10.1353/cpr.2019.0030.

PMID:
31378727
4.

Community-Academic Partnerships: Approaches to Engagement.

Noel L, Phillips F, Tossas-Milligan K, Spear K, Vanderford NL, Winn RA, Vanderpool RC, Eckhardt SG.

Am Soc Clin Oncol Educ Book. 2019 Jan;39:88-95. doi: 10.1200/EDBK_246229. Epub 2019 May 17.

PMID:
31099695
5.

Lung Cancer Screening and Epigenetics in African Americans: The Role of the Socioecological Framework.

Watson KS, Hulbert A, Henderson V, Chukwudozie IB, Aponte-Soto L, Lerner L, Martinez E, Kim S, Winn RA.

Front Oncol. 2019 Mar 12;9:87. doi: 10.3389/fonc.2019.00087. eCollection 2019.

6.

Society of Behavior Medicine (SBM) Urges Congress to Ensure Affordable Care Act Coverage of Prostate Cancer Screening Support Services for High-Risk Men.

Watson K, Buscemi J, Fitzgibbon M, Murray M, Murphy A, Abern M, Gann P, Levi JB, Stinson J, Diefenbach M, Winn RA.

Transl Behav Med. 2019 Mar 11. pii: ibz034. doi: 10.1093/tbm/ibz034. [Epub ahead of print]

PMID:
30855080
7.

Wnt7a induces a unique phenotype of monocyte-derived macrophages with lower phagocytic capacity and differential expression of pro- and anti-inflammatory cytokines.

Wallace J, Lutgen V, Avasarala S, St Croix B, Winn RA, Al-Harthi L.

Immunology. 2018 Feb;153(2):203-213. doi: 10.1111/imm.12830. Epub 2017 Oct 12.

8.

A geographic information system-based method for estimating cancer rates in non-census defined geographical areas.

Freeman VL, Boylan EE, Pugach O, Mclafferty SL, Tossas-Milligan KY, Watson KS, Winn RA.

Cancer Causes Control. 2017 Oct;28(10):1095-1104. doi: 10.1007/s10552-017-0941-8. Epub 2017 Aug 20.

9.

Downregulation of PKCζ/Pard3/Pard6b is responsible for lung adenocarcinoma cell EMT and invasion.

Zhou Q, Dai J, Chen T, Dada LA, Zhang X, Zhang W, DeCamp MM, Winn RA, Sznajder JI, Zhou G.

Cell Signal. 2017 Oct;38:49-59. doi: 10.1016/j.cellsig.2017.06.016. Epub 2017 Jun 24.

10.

K-homology splicing regulatory protein (KSRP) promotes post-transcriptional destabilization of Spry4 transcripts in non-small cell lung cancer.

Bikkavilli RK, Zerayesus SA, Van Scoyk M, Wilson L, Wu PY, Baskaran A, Tang K, Raheem S, Samuelson BA, Reddy NM, Reddy SP, Cool CD, Kosmider B, Avasarala S, Winn RA.

J Biol Chem. 2017 May 5;292(18):7423-7434. doi: 10.1074/jbc.M116.757906. Epub 2017 Mar 8.

11.

Orthogonal lipid sensors identify transbilayer asymmetry of plasma membrane cholesterol.

Liu SL, Sheng R, Jung JH, Wang L, Stec E, O'Connor MJ, Song S, Bikkavilli RK, Winn RA, Lee D, Baek K, Ueda K, Levitan I, Kim KP, Cho W.

Nat Chem Biol. 2017 Mar;13(3):268-274. doi: 10.1038/nchembio.2268. Epub 2016 Dec 26.

12.

Rationale and design of Mi-CARE: The mile square colorectal cancer screening, awareness and referral and education project.

Buscemi J, Miguel YS, Tussing-Humphreys L, Watts EA, Fitzgibbon ML, Watson K, Winn RA, Matthews KL, Molina Y.

Contemp Clin Trials. 2017 Jan;52:75-79. doi: 10.1016/j.cct.2016.11.009. Epub 2016 Nov 22.

13.

Society of Behavioral Medicine supports implementation of high quality lung cancer screening in high-risk populations.

Watson KS, Blok AC, Buscemi J, Molina Y, Fitzgibbon M, Simon MA, Williams L, Matthews K, Studts JL, Lillie SE, Ostroff JS, Carter-Harris L, Winn RA.

Transl Behav Med. 2016 Dec;6(4):669-671.

14.

Society of Behavioral Medicine (SBM) position statement: SBM supports the National Colorectal Cancer Roundtable's (NCCRT) call to action to reach 80 % colorectal cancer screening rates by 2018.

Becker EA, Buscemi J, Fitzgibbon ML, Watson K, Matthews KL, Winn RA; Society of Behavioral Medicine Health Policy Committee.

Transl Behav Med. 2016 Jun;6(2):306-8. doi: 10.1007/s13142-015-0364-6.

15.

Wnt7a is a novel inducer of β-catenin-independent tumor-suppressive cellular senescence in lung cancer.

Bikkavilli RK, Avasarala S, Van Scoyk M, Arcaroli J, Brzezinski C, Zhang W, Edwards MG, Rathinam MK, Zhou T, Tauler J, Borowicz S, Lussier YA, Parr BA, Cool CD, Winn RA.

Oncogene. 2015 Oct 16;34(42):5406. doi: 10.1038/onc.2015.165. No abstract available.

PMID:
26473947
16.

Novel Role for γ-Catenin in the Regulation of Cancer Cell Migration via the Induction of Hepatocyte Growth Factor Activator Inhibitor Type 1 (HAI-1).

Sechler M, Borowicz S, Van Scoyk M, Avasarala S, Zerayesus S, Edwards MG, Kumar Karuppusamy Rathinam M, Zhao X, Wu PY, Tang K, Bikkavilli RK, Winn RA.

J Biol Chem. 2015 Jun 19;290(25):15610-20. doi: 10.1074/jbc.M114.631820. Epub 2015 Apr 29.

17.

PRMT1 Is a Novel Regulator of Epithelial-Mesenchymal-Transition in Non-small Cell Lung Cancer.

Avasarala S, Van Scoyk M, Karuppusamy Rathinam MK, Zerayesus S, Zhao X, Zhang W, Pergande MR, Borgia JA, DeGregori J, Port JD, Winn RA, Bikkavilli RK.

J Biol Chem. 2015 May 22;290(21):13479-89. doi: 10.1074/jbc.M114.636050. Epub 2015 Apr 6.

18.

Wnt7a is a novel inducer of β-catenin-independent tumor-suppressive cellular senescence in lung cancer.

Bikkavilli RK, Avasarala S, Van Scoyk M, Arcaroli J, Brzezinski C, Zhang W, Edwards MG, Rathinam MK, Zhou T, Tauler J, Borowicz S, Lussier YA, Parr BA, Cool CD, Winn RA.

Oncogene. 2015 Oct 16;34(42):5317-28. doi: 10.1038/onc.2015.2. Epub 2015 Mar 2. Erratum in: Oncogene. 2015 Oct 16;34(42):5406.

19.

The soft agar colony formation assay.

Borowicz S, Van Scoyk M, Avasarala S, Karuppusamy Rathinam MK, Tauler J, Bikkavilli RK, Winn RA.

J Vis Exp. 2014 Oct 27;(92):e51998. doi: 10.3791/51998.

20.

In vitro methylation assay to study protein arginine methylation.

Bikkavilli RK, Avasarala S, Van Scoyk M, Karuppusamy Rathinam MK, Tauler J, Borowicz S, Winn RA.

J Vis Exp. 2014 Oct 5;(92):e51997. doi: 10.3791/51997.

21.

The histone demethylase KDM3A is a microRNA-22-regulated tumor promoter in Ewing Sarcoma.

Parrish JK, Sechler M, Winn RA, Jedlicka P.

Oncogene. 2015 Jan 8;34(2):257-62. doi: 10.1038/onc.2013.541. Epub 2013 Dec 23.

22.

Heterotrimeric G-protein, Gα16, is a critical downstream effector of non-canonical Wnt signaling and a potent inhibitor of transformed cell growth in non small cell lung cancer.

Avasarala S, Bikkavilli RK, Van Scoyk M, Zhang W, Lapite A, Hostetter L, Byers JT, Heasley LE, Sohn JW, Winn RA.

PLoS One. 2013 Oct 18;8(10):e76895. doi: 10.1371/journal.pone.0076895. eCollection 2013.

23.

Tumours with elevated levels of the Notch and Wnt pathways exhibit efficacy to PF-03084014, a γ-secretase inhibitor, in a preclinical colorectal explant model.

Arcaroli JJ, Quackenbush KS, Purkey A, Powell RW, Pitts TM, Bagby S, Tan AC, Cross B, McPhillips K, Song EK, Tai WM, Winn RA, Bikkavilli K, Vanscoyk M, Eckhardt SG, Messersmith WA.

Br J Cancer. 2013 Aug 6;109(3):667-75. doi: 10.1038/bjc.2013.361. Epub 2013 Jul 18.

24.

hsa-miR29b, a critical downstream target of non-canonical Wnt signaling, plays an anti-proliferative role in non-small cell lung cancer cells via targeting MDM2 expression.

Avasarala S, Van Scoyk M, Wang J, Sechler M, Vandervest K, Brzezinski C, Weekes C, Edwards MG, Arcaroli J, Davis RE, Bikkavilli RK, Winn RA.

Biol Open. 2013 May 22;2(7):675-85. doi: 10.1242/bio.20134507. Print 2013 Jul 15.

25.

Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer.

Spreafico A, Tentler JJ, Pitts TM, Tan AC, Gregory MA, Arcaroli JJ, Klauck PJ, McManus MC, Hansen RJ, Kim J, Micel LN, Selby HM, Newton TP, McPhillips KL, Gustafson DL, Degregori JV, Messersmith WA, Winn RA, Eckhardt SG.

Clin Cancer Res. 2013 Aug 1;19(15):4149-62. doi: 10.1158/1078-0432.CCR-12-3140. Epub 2013 Jun 11.

26.

Non-small-cell lung cancer: molecular targeted therapy and personalized medicine - drug resistance, mechanisms, and strategies.

Sechler M, Cizmic AD, Avasarala S, Van Scoyk M, Brzezinski C, Kelley N, Bikkavilli RK, Winn RA.

Pharmgenomics Pers Med. 2013 Apr 4;6:25-36. doi: 10.2147/PGPM.S26058. Print 2013.

27.

Dishevelled3 is a novel arginine methyl transferase substrate.

Bikkavilli RK, Avasarala S, Vanscoyk M, Sechler M, Kelley N, Malbon CC, Winn RA.

Sci Rep. 2012;2:805. doi: 10.1038/srep00805. Epub 2012 Nov 13.

28.

Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancer.

Weekes CD, Song D, Arcaroli J, Wilson LA, Rubio-Viqueira B, Cusatis G, Garrett-Mayer E, Messersmith WA, Winn RA, Hidalgo M.

Neoplasia. 2012 Aug;14(8):690-701.

29.

Methylation of Wnt7a is modulated by DNMT1 and cigarette smoke condensate in non-small cell lung cancer.

Tennis MA, Vanscoyk MM, Wilson LA, Kelley N, Winn RA.

PLoS One. 2012;7(3):e32921. doi: 10.1371/journal.pone.0032921. Epub 2012 Mar 5.

30.

"Un-slugging" resistance to epidermal growth factor receptor inhibition. A positive outlook for the future of lung cancer therapy.

Winn RA, Tuder RM.

Am J Respir Crit Care Med. 2011 Apr 15;183(8):970-2. doi: 10.1164/rccm.201012-1970ED. No abstract available.

PMID:
21498821
31.

The many faces of wnt and pancreatic ductal adenocarcinoma oncogenesis.

Weekes CD, Winn RA.

Cancers (Basel). 2011 Sep 21;3(3):3676-86. doi: 10.3390/cancers3033676.

32.

Sprouty-4 inhibits transformed cell growth, migration and invasion, and epithelial-mesenchymal transition, and is regulated by Wnt7A through PPARgamma in non-small cell lung cancer.

Tennis MA, Van Scoyk MM, Freeman SV, Vandervest KM, Nemenoff RA, Winn RA.

Mol Cancer Res. 2010 Jun;8(6):833-43. doi: 10.1158/1541-7786.MCR-09-0400. Epub 2010 May 25.

33.

Prostacyclin inhibits non-small cell lung cancer growth by a frizzled 9-dependent pathway that is blocked by secreted frizzled-related protein 1.

Tennis MA, Van Scoyk M, Heasley LE, Vandervest K, Weiser-Evans M, Freeman S, Keith RL, Simpson P, Nemenoff RA, Winn RA.

Neoplasia. 2010 Mar;12(3):244-53.

34.
35.

The role of prostacyclin in lung cancer.

Tennis MA, Vanscoyk M, Keith RL, Winn RA.

Transl Res. 2010 Feb;155(2):57-61. doi: 10.1016/j.trsl.2009.06.010. Epub 2009 Jul 23.

PMID:
20129485
36.

Depletion of cytosolic phospholipase A2 in bone marrow-derived macrophages protects against lung cancer progression and metastasis.

Weiser-Evans MC, Wang XQ, Amin J, Van Putten V, Choudhary R, Winn RA, Scheinman R, Simpson P, Geraci MW, Nemenoff RA.

Cancer Res. 2009 Mar 1;69(5):1733-8. doi: 10.1158/0008-5472.CAN-08-3766. Epub 2009 Feb 10.

37.

Prostacyclin prevents murine lung cancer independent of the membrane receptor by activation of peroxisomal proliferator--activated receptor gamma.

Nemenoff R, Meyer AM, Hudish TM, Mozer AB, Snee A, Narumiya S, Stearman RS, Winn RA, Weiser-Evans M, Geraci MW, Keith RL.

Cancer Prev Res (Phila). 2008 Oct;1(5):349-56. doi: 10.1158/1940-6207.CAPR-08-0145.

38.

Analysis of Wnt7a-stimulated JNK activity and cJun phosphorylation in non-small cell lung cancer cells.

Heasley LE, Winn RA.

Methods Mol Biol. 2008;468:187-96. doi: 10.1007/978-1-59745-249-6_14.

PMID:
19099255
39.

Oncogenic K-Ras regulates proliferation and cell junctions in lung epithelial cells through induction of cyclooxygenase-2 and activation of metalloproteinase-9.

Wang XQ, Li H, Van Putten V, Winn RA, Heasley LE, Nemenoff RA.

Mol Biol Cell. 2009 Feb;20(3):791-800. doi: 10.1091/mbc.E08-07-0732. Epub 2008 Nov 26.

40.

The cancer paradigm of severe pulmonary arterial hypertension.

Rai PR, Cool CD, King JA, Stevens T, Burns N, Winn RA, Kasper M, Voelkel NF.

Am J Respir Crit Care Med. 2008 Sep 15;178(6):558-64. doi: 10.1164/rccm.200709-1369PP. Epub 2008 Jun 12.

41.

Activation and Molecular Targets of Peroxisome Proliferator-Activated Receptor-gamma Ligands in Lung Cancer.

Nemenoff RA, Weiser-Evans M, Winn RA.

PPAR Res. 2008;2008:156875. doi: 10.1155/2008/156875.

42.

Wnt signaling pathway and lung disease.

Van Scoyk M, Randall J, Sergew A, Williams LM, Tennis M, Winn RA.

Transl Res. 2008 Apr;151(4):175-80. doi: 10.1016/j.trsl.2007.12.011. Epub 2008 Feb 5. Review.

PMID:
18355764
43.

Antitumorigenic effects of peroxisome proliferator-activated receptor-gamma in non-small-cell lung cancer cells are mediated by suppression of cyclooxygenase-2 via inhibition of nuclear factor-kappaB.

Bren-Mattison Y, Meyer AM, Van Putten V, Li H, Kuhn K, Stearman R, Weiser-Evans M, Winn RA, Heasley LE, Nemenoff RA.

Mol Pharmacol. 2008 Mar;73(3):709-17. Epub 2007 Nov 30.

PMID:
18055759
44.

Role of the wnt signaling pathway and lung cancer.

Tennis M, Van Scoyk M, Winn RA.

J Thorac Oncol. 2007 Oct;2(10):889-92. Review. No abstract available.

45.

Antitumorigenic effect of Wnt 7a and Fzd 9 in non-small cell lung cancer cells is mediated through ERK-5-dependent activation of peroxisome proliferator-activated receptor gamma.

Winn RA, Van Scoyk M, Hammond M, Rodriguez K, Crossno JT Jr, Heasley LE, Nemenoff RA.

J Biol Chem. 2006 Sep 15;281(37):26943-50. Epub 2006 Jul 11.

46.

Inhibited neurogenesis in JNK1-deficient embryonic stem cells.

Amura CR, Marek L, Winn RA, Heasley LE.

Mol Cell Biol. 2005 Dec;25(24):10791-802.

47.

Beta-catenin in the fibroproliferative response to acute lung injury.

Douglas IS, Diaz del Valle F, Winn RA, Voelkel NF.

Am J Respir Cell Mol Biol. 2006 Mar;34(3):274-85. Epub 2005 Nov 4.

48.

Role of nuclear receptors in lung tumourigenesis.

Nemenoff RA, Winn RA.

Eur J Cancer. 2005 Nov;41(16):2561-8. Epub 2005 Sep 30. Review.

PMID:
16199155
49.

A middle-aged woman with recurrent respiratory infections.

Chmura K, Chan ED, Noone PG, Zariwala M, Winn RA, Knowles MR, Iseman MD, Gardner EM.

Respiration. 2005 Jul-Aug;72(4):427-30. No abstract available.

PMID:
16088289
50.

Restoration of Wnt-7a expression reverses non-small cell lung cancer cellular transformation through frizzled-9-mediated growth inhibition and promotion of cell differentiation.

Winn RA, Marek L, Han SY, Rodriguez K, Rodriguez N, Hammond M, Van Scoyk M, Acosta H, Mirus J, Barry N, Bren-Mattison Y, Van Raay TJ, Nemenoff RA, Heasley LE.

J Biol Chem. 2005 May 20;280(20):19625-34. Epub 2005 Feb 10.

Supplemental Content

Support Center